Myasthenia Gravis - Market Insight, Epidemiology And Market Forecast - 2034

Key Highlights

DelveInsight estimates that in 2024, there were approximately 310,000 total diagnosed prevalent cases of myasthenia gravis across the 7MM.

In 2024, within the US, myasthenia gravis demonstrated a slight male predominance, with around 69,000 diagnosed cases in males compared to nearly 68,000 in females.

According to DelveInsight’s analysis, the myasthenia gravis market in the 7MM was valued at approximately USD 4,500 in 2024. Over the forecast period from 2025 to 2034, this market is projected to grow at a Compound Annual Growth Rate (CAGR) of 10.4%.

A range of targeted therapies has transformed myasthenia gravis treatment, including Neonatal Fc Receptor (FcRn) inhibitors like RYSTIGGO, VYVGART, VYVGART HYTRULO/VYVDURA, IMAAVY; complement inhibitors such as SOLIRIS and ULTOMIRIS and the Complement C5 inhibitor ZILBRYSQ. These advances reflect a shift toward precision immunotherapy and improved patient outcomes.

The focus of treatment is shifting from short-term symptom control to restoring long-term immune balance by targeting antibody production and B-cell activity. This evolving approach, seen across autoimmune diseases, is driving innovation in the myasthenia gravis pipeline, with candidates like RNA CAR T-cell therapy (Descartes-08), dual complement inhibitors (pozelimab + cemdisiran), and BLyS/APRIL pathway blockers (telitacicept) reflecting this trend.

A key unmet need in myasthenia gravis treatment is the lack of fast-acting, long-lasting therapies with better safety profiles. While newer targeted drugs have improved outcomes, many patients still experience delayed relief, relapses, or adverse effects, highlighting the need for more personalized and consistently effective treatment options.

DelveInsight’s “Myasthenia Gravis – Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of myasthenia gravis, historical and forecasted epidemiology, as well as the myasthenia gravis market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The myasthenia gravis market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM myasthenia gravis market size from 2020 to 2034. The report also covers myasthenia gravis treatment practices/algorithm myasthenia gravis and unmet medical needs to curate the best opportunities and assess the market’s potential.

Myasthenia Gravis Understanding and Treatment Algorithm

Myasthenia Gravis overview

Myasthenia gravis is a long-term autoimmune neuromuscular disorder marked by muscle weakness and rapid fatigue due to disrupted communication at the neuromuscular junction. This dysfunction results from antibodies that interfere with receptors essential for muscle contraction. Common symptoms include drooping eyelids, double vision, speech and swallowing difficulties, and weakness that intensifies with activity but improves with rest. The severity of the disease varies, with some individuals experiencing relapses and remissions, while others may develop life-threatening respiratory complications. Though rarely fatal, it can greatly affect quality of life if not identified and treated early. Advances in diagnostics and targeted treatments are enhancing patient outcomes.

Myasthenia Gravis diagnosis

Diagnosing myasthenia gravis requires a multifaceted approach, as no single test is conclusive. Clinicians begin with a detailed clinical evaluation to assess fluctuating muscle weakness and fatigue. Antibody testing for Acetylcholine Receptor (AChR) and Muscle-Specific Kinase (MuSK) provides strong diagnostic clues, while Electromyography (EMG) and repetitive nerve stimulation confirm impaired neuromuscular transmission. Imaging, such as Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) of the chest, is used to detect a thymoma, often linked to the condition. In select cases, the edrophonium test may offer rapid diagnostic insight. Timely and accurate diagnosis is essential, as early intervention significantly improves long-term outcomes.

Myasthenia Gravis treatment

While myasthenia gravis has no definitive cure, several treatments are available to manage symptoms, improve muscle strength, and prevent disease worsening. During acute exacerbations, high-dose intravenous corticosteroids like methylprednisolone are often administered over 3–5 days to suppress immune activity and rapidly relieve muscle weakness. This may be followed by a tapering course of oral steroids. Though effective for short-term symptom control, steroids do not alter the long-term disease course. For sustained management, patients are typically started on immunosuppressive therapies—such as azathioprine, mycophenolate mofetil, or cyclosporine—which reduce antibody production and help prevent relapses. In moderate to severe or refractory cases, advanced treatments like IVIG, plasmapheresis, or targeted biologics (e.g., FcRn inhibitors or complement blockers) are used to control disease activity and maintain long-term function.

Myasthenia Gravis Epidemiology

As the market is derived using a patient-based model, the myasthenia gravis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of myasthenia gravis, gender-specific diagnosed prevalent cases of myasthenia gravis, age-specific diagnosed prevalent cases of myasthenia gravis, severity-specific diagnosed prevalent cases of myasthenia gravis by MGFA classification and diagnosed prevalent cases of gMG by antibody serology in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.

In 2024, approximately 137,000 in the US were living with a diagnosed prevalent case of myasthenia gravis, with this number expected to increase by 2034 due to improved disease recognition and diagnostic advancements.

In 2024, females accounted for approximately 52% of diagnosed myasthenia gravis cases in Germany, compared to 48% in males, indicating a modest but consistent gender disparity, with females representing a slightly higher disease burden.

Among EU4 and the UK, Germany had the highest number of diagnosed prevalent cases of myasthenia gravis in 2024, with approximately 37,000 cases, while Spain recorded the lowest, with around 14,000 cases.

As of 2024, in EU4 and the UK, mild gMG (Class II) was the most prevalent severity classification, affecting approximately 50,000 individuals. This was followed by ocular myasthenia gravis (Class I) with more than 45,000 cases and moderate generalized (Class III) with more than 28,000 cases. Severe gMG (Class IV) accounted for nearly 7,000 individuals, while the most critical form, Class V (requiring intubation), affected more than 2,000 individuals. This distribution highlights the predominance of milder forms and emphasizes the importance of early diagnosis and intervention to prevent disease progression.

In Japan, as of 2024, the antibody serology profile among individuals with gMG shows that approximately 19,000 patients were positive for anti-AChR antibodies, around 1,000 for anti-MuSK antibodies, and nearly 2,000 were double seronegative, including those with anti-LRP4, anti-argin, or other less common antibodies. This distribution underscores the predominance of anti-AChR–positive cases and highlights the importance of antibody-specific diagnostic and therapeutic strategies.

Myasthenia Gravis Drug Chapters

The drug chapter segment of the myasthenia gravis report encloses a detailed analysis of myasthenia gravis-marketed drugs and pipeline drugs. It also helps understand the myasthenia gravis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Marketed Drugs

ULTOMIRIS (ravulizumab): Alexion: AstraZeneca Rare Disease

ULTOMIRIS is the first and only long-acting C5 complement inhibitor, designed to provide immediate, complete, and sustained inhibition of terminal complement activity. By specifically binding to complement protein C5, ULTOMIRIS blocks its cleavage, preventing uncontrolled complement activation that can damage healthy cells. It is administered intravenously every 8 weeks in adults, following an initial loading dose, offering patients a more convenient dosing schedule compared to first-generation therapies. ULTOMIRIS is approved for the treatment of PNH, aHUS, gMG in anti-AChR antibody-positive adults, and NMOSD in anti-aquaporin-4 AQP4 antibody-positive adults, delivering transformative care for these severe complement-mediated diseases.

In April 2025, Alexion, AstraZeneca Rare Disease, will present 21 abstracts at the AAN Annual Meeting, including new clinical and real-world data on ULTOMIRIS (ravulizumab-cwvz) and SOLIRIS (eculizumab) in NMOSD and gMG.

ULTOMIRIS patents are anticipated to expire by 2035 and 2038 in the US and Europe and by 2037 and 2038 in Japan.

VYVGART (efgartigimod alfa-fcab): Argenx

VYVGART is an approved FcRn blocker designed to reduce circulating IgG autoantibodies that drive disease activity in gMG. By specifically binding to the FcRn, VYVGART accelerates the breakdown of pathogenic IgG antibodies, including those targeting the acetylcholine receptor, which disrupt nerve–muscle communication and cause muscle weakness. VYVGART is approved in the United States and Europe for the treatment of adults with gMG who are anti-AChR antibody-positive, and in Japan for adults with gMG who do not respond adequately to steroids or other nonsteroidal immunosuppressive therapies. Argenx is advancing a multidimensional expansion strategy for VYVGART, including additional regulatory submissions in gMG, the launch of subcutaneous efgartigimod, and new indications such as immune thrombocytopenia (ITP).

The regulatory exclusivity period for VVVGART is expected to extend until December 2033 in the US. Regulatory protection in the EU (both orphan and data/marketing exclusivity) is expected to expire in August 2032 in the European Economic Area (EEA).

In December 2023, the EU Commission granted marketing authorization for SC VYVGART as an add-on to standard therapy for the treatment of adult patients with gMG who are AChR antibody-positive, expanding on the initial IV approval granted in August 2022 across the VYVGART-approved countries.

Emerging Drugs

Descartes-08: Cartesian Therapeutics

Descartes-08 is a first-in-class RNA CAR-T in clinical development for myasthenia gravis and other autoimmune diseases. Compared to conventional DNA-based CAR T-cell therapies, RNA CAR-T has predictable and controllable pharmacokinetics and avoids the risk of genomic integration. These attributes are expected to make Descartes-08 safer than DNA-based cell therapies. Descartes-08 is a personalized (autologous) therapy during which cells are collected, engineered with RNA, and returned to the same individual in the outpatient setting. A course of therapy consists of 6 weekly infusions.

In December 2024, Cartesian Therapeutics, which is pioneering mRNA cell therapies for autoimmune diseases, announced positive updated results from its Phase IIb trial of Descartes-08 in participants with myasthenia gravis and outlined the design of its planned Phase III AURORA trial.

In November 2023, Selecta Biosciences merged with Cartesian Therapeutics, a clinical-stage biotechnology company pioneering RNA cell therapies for autoimmune diseases.

Gefurulimab (ALXN-1720): Alexion, AstraZeneca Rare Disease

Gefurulimab is an investigational, anti-C5 albumin-binding humanized bispecific VHH antibody optimized for subcutaneous delivery. Gefurulimab is under development for treating gMG and proteinuria.

Upon administration, gefurulimab, with its anti-C5 antibody moiety, targets and binds to terminal complement protein C5, thereby blocking the terminal complement pathway of complement activation. This inhibits complement-mediated inflammation and cell lysis. Excessive complement activation plays a key role in various inflammatory and autoimmune diseases and destroys tissue. The binding of gefurulimab to albumin, with its albumin binding domain, increases its half-life. Currently, the drug is in Phase III of clinical development to treat gMG.

Alexion, AstraZeneca Rare Disease stated that the Phase III readout for Gefurulimab in gMG is expected in the second-half of 2025, potentially positioning it as a meaningful addition to the treatment landscape.

AstraZeneca plans to file regulatory submissions for myasthenia gravis in 2024.

FABHALTA (Iptacopan): Novartis

Iptacopan (LNP023) is an orally administered small-molecule inhibitor that targets the complement system, a critical driver of inflammation and autoimmune pathology. It acts by selectively inhibiting Factor B, a central protein in the alternative complement pathway. This inhibition prevents the formation of C3 and C5 convertases, effectively blocking downstream complement activation and reducing immune-mediated tissue damage and cell destruction. The drug is marketed as FABHALTA and has already been approved for use in another indication. Novartis plans to submit Phase III data for gMG by 2027.

Drug Class Insights

The treatment paradigm for myasthenia gravis is undergoing a transformative shift from broad immunosuppression and symptomatic relief to targeted, disease-modifying strategies tailored to individual immune profiles. While acute exacerbations and crises are still managed with corticosteroids, intravenous immunoglobulin (IVIg), or plasmapheresis, long-term therapy is increasingly focused on precision biologics that address the underlying autoimmune mechanisms. Complement inhibitors such as ULTOMIRIS (ravulizumab), and ZILBRYSQ (zilucoplan) have demonstrated robust efficacy in reducing complement-mediated damage at the neuromuscular junction. FcRn antagonists, including VYVGART (efgartigimod), RYSTIGGO (rozanolixizumab), and the newly approved IMAAVY (nipocalimab), represent a major advancement by lowering pathogenic IgG levels in both AChR and MuSK antibody-positive patients. The development pipeline is rich with next-generation therapies, including the BTK inhibitor remibrutinib, dual complement inhibition with pozelimab + cemdisiran (Regeneron), B-cell-targeted agents such as TELITACICEPT, MAVENCLAD (cladribine), and UPLIZNA (inebilizumab), and innovative cell therapies like Descartes-08, a transient mRNA CAR-T platform. Together, these advancements reflect a clear movement toward personalized, immunopathology-driven treatment aimed at achieving sustained disease control, minimizing relapses, and improving long-term quality of life for patients with MG.

Continued in report…

Market Outlook

Myasthenia gravis is a chronic autoimmune neuromuscular disorder marked by fluctuating muscle weakness due to B-cell-driven production of antibodies against AChR or MuSK at the neuromuscular junction. First-line management continues to rely on symptomatic agents like pyridostigmine and immunosuppressants such as corticosteroids and nonsteroidal ISTs (azathioprine, MMF), yet long-term remission remains elusive for many. Rescue therapies like IVIg and plasmapheresis are used in acute exacerbations, especially in refractory patients who comprise up to 15% of the population. The treatment paradigm is rapidly evolving with the advent of targeted biologics. Complement inhibitors—SOLIRIS, ULTOMIRIS, and ZILBRYSQ—address terminal complement activation to prevent neuromuscular damage, while FcRn antagonists like VYVGART, RYSTIGGO, and IMAAVY reduce pathogenic IgG levels, offering disease control for both AChR- and MuSK-positive patients. Recent real-world data across the US, EU, and Japan reveal persistent reliance on conventional therapies, limited early biologic uptake, and high variability in prescribing practices, especially for elderly or refractory populations. However, growing approvals and broader access to subcutaneous biologics signal a shift toward precision immunotherapy, positioning myasthenia gravis as a leading indication in the neuromuscular rare disease market with substantial clinical and commercial potential.

Companies like Cartesian Therapeutics (Descartes-08), Novartis (Remibrutinib), Alexion: AstraZeneca Rare Disease (Gefurulimab), and Merck KGaA (Cladribine), etc, among others are involved in the development of Phase III, Phase II and Phase I drugs.

The market size for myasthenia gravis in the US was approximately USD 2,900 million in 2024 and is anticipated to increase due to the launch of emerging therapies.

The total market size of EU4 and the UK was calculated to be approximately USD 1,200 million in 2024, which was nearly 27% of the total market revenue for the 7MM and is expected to increase by 2034.

In 2024, Germany dominated the market among EU4 and the UK, generating around USD 400 million. France followed closely with approximately USD 300 million, while Italy recorded around USD 200 million.

In 2024, the total market size of myasthenia gravis was approximately USD 350 million in Japan, which is anticipated to increase during the forecast period (2025-2034).

Myasthenia Gravis Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2020–2034.

Further detailed analysis of emerging therapies drug uptake in the report…

Myasthenia Gravis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics.

Pipeline development activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for emerging therapies for myasthenia gravis.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on myasthenia gravis evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Medical Professionals, Professors, Directors, and Others.

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers like the Johns Hopkins University, US, University Hospital Ulm, Germany, Charité University Hospital Berlin, Germany, Paris-Saclay University, France, University of Ferrara, Italy, Autonomous University of Barcelona, Spain, The University of Manchester, UK, Kanazawa University, Japan, and Nippon Medical School, Japan, among others, were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or myasthenia gravis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Physician’s View

As per KOLs from the US, there remains a critical unmet need in the management of myasthenia gravis, particularly for patients with treatment-refractory disease and those experiencing significant side effects from chronic immunosuppression. While advances have been made, current treatment strategies still rely heavily on generalized immunomodulation, which may not offer sustained disease control or tolerability for all patients. There is growing consensus that the future of care must move toward mechanism-based, individualized approaches, supported by earlier diagnosis, improved disease monitoring, and streamlined access to advanced therapies, to truly optimize outcomes and quality of life for individuals living with myasthenia gravis.

As per KOLs from the UK, delayed diagnosis continues to be a major unmet need in myasthenia gravis. Early symptoms are often misattributed to non-neuromuscular conditions, leading to diagnostic delays and suboptimal early management. There is a growing emphasis on raising awareness among general practitioners and ensuring faster access to confirmatory testing, particularly for seronegative cases, to enable earlier intervention and better long-term outcomes.

As per KOLs from Japan, long-term management of myasthenia gravis remains heavily dependent on generalized immunosuppression, which can lead to cumulative side effects and poor tolerability, especially in elderly or comorbid populations. There is a pressing need for more targeted, durable treatment options that minimize immune system disruption while providing consistent disease control—signaling a shift toward personalized immunotherapeutic approaches.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Attribute Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in term myasthenia gravis of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Attribute Analysis analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

To assess the effectiveness of these therapies, a comparative analysis was conducted using the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, a validated tool for measuring functional impairment in individuals with myasthenia gravis. Each therapy was evaluated based on its impact on MG-ADL outcomes, allowing a structured assessment of how well treatments improve daily functioning and reduce disease burden. This scoring approach offers meaningful insight into the real-world performance of myasthenia gravis therapies beyond traditional clinical endpoints such as exacerbation rates or antibody titers.

Further, the therapies’ safety is evaluated wherein the adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials, which directly affects the safety of the molecule in the upcoming trials. It sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

? VYVGART and VYVGART HYTRULO: Argenx

Co-pay Program

My VYVGART path commercial co-payment program is a patient support program that provides personalized support from committed nurse case managers and access managers.

Eligible patients may pay as little as USD 0 per injection of VYVGART with a maximum benefit per calendar year of USD 25,000.

The financial assistance provided under the co-pay program is to be applied to the patient’s out-of-pocket costs for VYVGART and the associated administration of VYVGART (e.g., product administration costs).

Patients residing in Massachusetts and Rhode Island are eligible for financial assistance with medication costs for VYVGART, but are ineligible for financial assistance related to administration costs.

If a patient’s financial responsibility for the medication and associated administration of VYVGART is greater than the maximum financial assistance that can be provided in a given calendar year, the patient will be responsible for any remaining out-of-pocket costs for the medication and associated administration of VYVGART for that calendar year.

The maximum financial assistance to eligible patients via the co-pay program is USD 25,000 per calendar year.

Further details will be provided in the report.

The report provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenarios, program myasthenia gravis making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug program myasthenia gravis, etc.

Scope of the Report

The report covers a segment of key events, an executive summary, and a descriptive overview of myasthenia gravis, explaining its causes, signs and symptom myasthenia gravis, pathogenesis, and currently available therapies.

Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines have been provided.

Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will affect the current treatment landscape.

A detailed review of the myasthenia gravis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.

The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM myasthenia gravis market.

Myasthenia Gravis Report Insights

Patient Population

Therapeutic Approaches

Myasthenia Gravis Pipeline Analysis

Myasthenia Gravis Market Size and Trends

Existing and Future Market Opportunity

Myasthenia Gravis Report Key Strengths

10 years Forecast

The 7MM Coverage

Myasthenia Gravis Epidemiology Segmentation

Key Cross Competition

Attribute analysis

Drugs Uptake and Key Market Forecast Assumptions

Myasthenia Gravis Report Assessment

Current Treatment Practices

Unmet Needs

Pipeline Product Profiles

Market Attractiveness

Qualitative Analysis (SWOT and Attribute Analysis)

Key Questions

Market Insights

What was the total market size of myasthenia gravis, the market size of myasthenia gravis by therapies, and market share (%) distribution in 2020, and what would it look like by 2034? What are the contributing factors for this growth?

How will IMAAVY affect the treatment paradigm of myasthenia gravis?

How will remibrutinib compete with other upcoming products and marketed therapies?

Which drug is going to be the largest contributor by 2034?

What are the pricing variations among different geographies for approved and marketed therapies?

How would future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

What are the disease risks, burdens, and unmet needs of myasthenia gravis? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to myasthenia gravis?

What is the historical and forecasted myasthenia gravis patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?

Out of the countries mentioned above, which country would have the highest diagnosed prevalent myasthenia gravis population during the forecast period (2025–2034)?

What factors are contributing to the growth of myasthenia gravis cases?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

What are the current options for the treatment of myasthenia gravis? What are the current clinical and treatment guidelines for treating myasthenia gravis?

How many companies are developing therapies for the treatment of myasthenia gravis?

How many emerging therapies are in the mid-stage and late stage of development for treating myasthenia gravis?

What are the recent novel therapies, targets, mechanism myasthenia gravis of action, and technologies developed to overcome the limitations of existing therapies?

What is the cost burden of current treatment on the patient?

Patient acceptability in term myasthenia gravis of preferred treatment options as per real-world scenarios?

What are the accessibility issues of approved therapy in the US?

What is the 7MM historical and forecasted market of myasthenia gravis?

Reasons to Buy

The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the myasthenia gravis market.

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

Understand the existing market opportunities in varying geographies and the growth potential over the coming years.

The distribution of historical and current patient share is based on real-world prescription data in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Identifying upcoming solid players in the market will help devise strategies to help get ahead of competitors.

Detailed analysis, ranking of class-wise potential current, and emerging therapies under the attribute analysis section to provide visibility around leading classes.

Highlights of Access and Reimbursement policies for myasthenia gravis, barriers to accessibility of approved therapy, and patient assistance program myasthenia gravis.

To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.

Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy. Show more